Amgen's Humira copy succeeds in skin disease trial

October 8, 2014 4:21 PM

15 0

(Reuters) - Amgen Inc said its copycat version of AbbVie Inc's blockbuster biotech drug Humira showed comparable safety and ability to generate immune response in patients with a type of skin disease.

The drug, ABP 501, was being tested in a late-stage trial in patients with plaque psoriasis, a skin disease caused by dysfunction of the immune system and which leads to painful, itchy red patches.

Read more

To category page